CBpromise   

Our promise to you:
Guaranteed product quality, expert customer support.

24x7 CUSTOMER SERVICE
CONTACT US TO ORDER

PDK1 Gene Editing    

PDK1 (3-phosphoinositide-dependent kinase 1) is a key member of the AGC protein kinase family and is capable of phosphorylating and activating at least 23 AGC kinases, including the AKT isoform (also known as PKB), p70 ribosomal S6 kinase ( S6K), serum and glucocorticoid-dependent kinase (SGK), P90 ribosomal S6 kinase (RSK), and atypical protein kinase (PKC). PDK1 is a key node in the PI3K pathway and contains 556 amino acids with a Pleckstrin homology (PH) domain and a catalytic domain characterized by a typical bilobal kinase fold in which the ATP cofactor is sandwiched between the amino terminal leaflet and the carboxy terminus larger leaves. PDK1 has five constantly phosphorylated Ser residues that are unaffected by the action of insulin. One of them, Ser241, is a prerequisite for PDK1 activity, and it appears that PDK1 is autophosphorylated on this residue. PDK1 is constitutively active, and phosphoinositide is responsible for converting its substrate into a form that is susceptible to phosphorylation by PDK1.

In many human tumor cells, PDK1 shows high levels of expression. Interestingly, an increase in the copy number of the PDK1 gene is often associated with other genetic mutations in the PI3K/AKT pathway (ERBB2 amplification, PTEN deletion or PIK3CA mutation) and poor patient prognosis. In addition, high PDK1 expression is related to advanced tumors (high lymph node metastasis or high histological grade) and short overall survival. Therefore, PDK1 expression can be used as a prognostic marker for this type of tumor. In hepatocellular carcinoma, the expression of PDK1 in cancer samples is higher than that in adjacent tissues. High PDK1 expression is associated with short postoperative overall survival and high recurrence rate (Figure 1).

Figure 1: Major pathways in chemoresistance and PDK1 implication (Aikaterini Emmanouilidi. 2017)

PDK1 Gene Editing Service

CRISPR/Cas9 PlatformCB, a global leading biotechnological company specializing in gene editing, is dedicated to offering comprehensive CRISPR/Cas9 gene editing services and products to a wide range of genomics researchers in the market. With deep gene editing knowledge and extensive experience in experimental operation and data processing, we can help you effectively control target genes deleted, inserted or point mutated in vivo and in vitro with CRISPR/Cas9 technology.

  • PDK1 Gene Editing Cell Line Generation

Based on our platform, we have successfully implemented PDK1 CRISPR/Cas9 gene edited in both easy-to-transfect cell lines and hard-to-transfect cells. To support your project, we offer you full-length custom PDK1 gene editing service from strategy design to final stable cells.

➢ Our PDK1 gene editing cell line generation services include

✔ gRNA design and synthesis
✔ Transfect the cell lines you’re interested
✔ Select the high expression cells and sort monoclonal cell
✔ Validate the knockout/knockin/point mutation of PDK1 by PCR and sequencing
✔ Produce cryogenic preserved vials of stable cells and a final report

➢ Cell lines we offered

✔ Blood Lineage Cells (RAW264.7, HMC1.2, K562, U937 etc.)
✔ Cancer Cell Lines (HEK293, HEK293T, Hela, MCF7, Neuro2a, HepG2, U87, etc.)
✔ Stem Cells (iPSC)
✔ Other Cell Lines (NIH3T3, MCF10, HEME, SW10 etc.

  • PDK1 Gene Editing Animal Model Generation

CRISPR/Cas9 PlatformCB also has extensive experience in incorporating CRISPR/as9 technology into animal models, which have been fully recognized by our clients. Tell us your needs, we provide a one-stop-shop PDK1 CRISPR/Cas9 gene editing animal service and guarantee at least 2 founders or 3 F1 animals with shorter turnaround time and lower price.

➢ Our PDK1 gene editing animal model generation services include

✔ PDK1 gene conventional knockout animals
✔ PDK1 gene conditional knockout animals
✔ PDK1 point mutation animals
✔ PDK1 knockin animals

➢ Alternative species: mouse, rat, rabbit, zebrafish, C. elegans, etc.

CRISPR/Cas9 PlatformCB is devoted to providing the best gene editing services and products for academic research, biotech research and pharmaceutical drug discovery with excellent quality management and quality assurance capacity. Our gene editing expert team provides you with custom CRISPR/Cas9 services for any specific gene to help you solve problems encountered during your research. If you have any project need CRISPR system, please feel free to contact us.

Related Products at CRISPR/Cas9 PlatformCB

CATALOG NO.PRODUCT NAMEINQUIRY
CLKO-0338PDK1 KO Cell Lysate-HeLaInquiry
CSC-RT0835Human PDK1 Knockout Cell Line-HeLaInquiry

References

  1. Paolo Armando Gagliardi. et al. PDK1: At the crossroad of cancer signaling pathways. Seminars in Cancer Biology. 2018; 48: 27-35.
  2. Keum-Jin Yang. et al. Regulation of 3-Phosphoinositide-dependent Protein Kinase-1 (PDK1) by Src Involves Tyrosine Phosphorylation of PDK1 and Src Homology 2 Domain Binding. The Journal of Biological Chemistry. 2008; 283:1480-1491.
  3. Gagliardi, P. A. et al. PDK1: At the crossroad of cancer signaling pathways. Seminars in Cancer Biology. 2018; 48:27-35.
  4. Aikaterini Emmanouilidi and Marco Falasca. Targeting PDK1 for Chemosensitization of Cancer Cells. Cancers. 2017; 9(10):140.
For research use only. Not intended for any clinical use.
Inquiry